PRINT THIS PAGE Alloy Ventures closes on early-stage venture capital fund13/10/2005. Source: AltAssets. 
 Alloy Ventures has announced the closing of its fifth venture fund, Alloy Ventures 2005. With commitments of $368m in this fund the total capital under management has surpassed $1bn.
The firm will continue to focus on seed and early-stage investing through a balanced portfolio of information technology and life science companies.
Craig C. Taylor, an Alloy general partner, said, "We were pleased to see that a moderately-sized fund investing in both information technology and life sciences continues to have tremendous appeal to both existing and new limited partners. Since June the fund has closed equity investments in four companies and moved into a larger facility to accommodate the expanded investment team."
Representative information technology investments currently in the portfolio include 3Leaf Networks, Gradient Design Automation, Integrated Materials, IPExtreme, NetZentry, and ViVOtech. Representative life science investments currently in the portfolio include Alexza Molecular Delivery Corp, Arbor Surgical, Barrx, Codon Devices, Fluidigm, ForteBio, Pacific Biosciences of California and SynergEyes.
Joining Alloy Ventures this year as general partners are: Michael W. Hunkapiller, Ph.D, most recently President and General Manager of Applied Biosystems; and Ammar H. Hanafi who had worked at Cisco Systems for eight years, most recently as Vice President of New Business Ventures.
Alloy's six other GPs are: J. Leighton Read, M.D., who joined Alloy in 2001 from Aviron, a biopharmaceutical company that he founded in 1992 and served as Chairman and Chief Executive Officer until 1999; Daniel I Rubin, a co-founder of Artisan Components, who joined the firm in 1999 and since 2003 has contributed as a general partner; and Craig C. Taylor, John. F. Shoch, Ph.D., Douglas E. Kelly, M.D., and Tony Di Bona, all of whom have worked together at Alloy Ventures for 12 years.
Copyright © 2005 AltAssets
|
